Takeda Pharmaceutical Co.
TAK Healthcare Drug Manufacturers Specialty & Generic
Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025. In the quarter to June 2026, revenue grew 1.71%, EPS fell 4.35%, free cash flow fell 95.6% and total debt fell 2.58%, each against the same quarter a year earlier.
Follow TAK
Takeda Pharmaceutical Co. (TAK) Dividend Safety Score
Takeda Pharmaceutical Co.'s stockrow Dividend Safety Score is 25 out of 100, based on payout ratios, leverage, dividend streak and earnings stability for fiscal 2026.
Dividend Safety Score, annual
Embed this chart
Annual newest first
| Period | Dividend Safety Score | Change (points) |
|---|---|---|
| FY2026 | 25 | — |
How fiscal 2026’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Payout of earnings earnings at or below zero | — | — | Fail | 0 |
| Payout of free cash flow | 49.26% | — | Pass | 25 |
| Net debt / EBITDA | 5.84 | — | Fail | 0 |
| Years without a dividend cut | 0 | — | Fail | 0 |
| Years of falling or negative earnings over the last 10 fiscal years | 6 | — | Fail | 0 |
| Dividend Safety Score | Weakly covered | 25 | ||
How the stockrow Dividend Safety Score works
Our own composite, out of 100, for the latest fiscal year: up to 25 points for how little of its earnings the dividend takes, 25 for how little of its free cash flow, 20 for net debt against EBITDA, 20 for the years it has paid without a cut and 10 for how steady earnings per share have been over ten years. How we calculate it.
| 80–100 | Well covered |
|---|---|
| 60–79 | Adequately covered |
| 40–59 | Stretched |
| below 40 | Weakly covered |
Not worked out for a company that pays no regular dividend, for banks and REITs, whose payouts and leverage these measures do not describe, or with fewer than five years of earnings.
Dividend Safety Score against peers
| Company | Dividend Safety Score |
|---|---|
| ZTS Zoetis Inc. compare | 88 |
| RDY Dr. Reddy's Laboratories Ltd compare | 74 |
| HLN Haleon PLC Sponsored ADR compare | 66 |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 52 |
| VTRS Viatris Inc. compare | 37 |
| TAK Takeda Pharmaceutical Co. | 25 |
| NBIX Neurocrine Biosciences, Inc. compare | — |
| ELAN Elanco Animal Health Incorporated compare | — |
| UTHR United Therapeutics Corporation compare | — |
What Dividend Safety Score is
The stockrow Dividend Safety Score rates how well earnings and free cash flow cover the dividend, with leverage, the dividend’s record and stable earnings.
Up to 25 points for the payout of earnings, 25 for the payout of free cash flow, 20 for net debt ÷ EBITDA, 20 for the years without a dividend cut and 10 for stable earnings